ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,187.46
0.28%
Dow Jones
41,198.08
0.59%
Gold vs US Dollar
2,467.65
0.25%
Brent Oil
84.715
0.27%
Bitcoin
64,553.57
0.73%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
18/07/202406:00UK RegulatoryCoop Pank unaudited financial results for Q2 2024
18/07/202406:00UK RegulatoryBioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHDEU:BIOSBiosenic
18/07/202406:00UK RegulatoryStart of Day Message
18/07/202406:00UK RegulatoryTelia Lietuva results for 6 months of 2024LSE:0G8JTelia Lietuva Ab
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseTG:05YVivoryon Therapeut
18/07/202406:00UK RegulatoryHexagon Purus ASA: Results for the second quarter 2024TG:0QJHexagon Purus ASA
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseEU:VVYVivoryon Therapeut
18/07/202406:00UK RegulatoryTGS Announces Q2 2024 ResultsTG:TGCTGS ASA
18/07/202406:00UK RegulatoryBioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHDEU:BIOSBiosenic
18/07/202406:00UK RegulatoryHexagon Purus ASA: Results for the second quarter 2024LSE:0AC1Hexagon Purus Asa
18/07/202406:00UK RegulatoryBioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHDLSE:0R55Biosenic Sa
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
18/07/202406:00UK RegulatoryBioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHDLSE:0R55Biosenic Sa
18/07/202406:00UK RegulatoryNokia Corporation Report for Q2 and Half Year 2024BIT:1NOKIANokia Corp
18/07/202405:55UK RegulatoryTGS Announces Extension to its Ocean Bottom Node Acquisition Campaign in West AfricaTG:TGCTGS ASA
18/07/202405:50Alliance NewsAlliance NewsGLOBAL BRIEFING: Japan returns to trade surplus on weaker imports
18/07/202405:48PR Newswire (US)BSI receives ISO 37001 certification from Speeki Europe
18/07/202405:42PR Newswire (US)BSI receives ISO 37001 certification from Speeki Europe
18/07/202405:20PR Newswire (US)PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Programme
18/07/202405:02PR Newswire (US)2024 MITSUBISHI OUTLANDER HAS YOUR BACK WITH A HOST OF SAFETY FEATURES
18/07/202405:01PR Newswire (US)Quantum Computing On Track to Create Up to $850 Billion of Economic Value By 2040
18/07/202405:00PR Newswire (US)Urgent Revelation: Psychology Originated Within Christian Theology, Not As A Secular Discipline
18/07/202405:00PR Newswire (US)OKX Ventures Announces Investment in zkLink to Unify Liquidity with Aggregated Rollups
18/07/202405:00PR Newswire (US)God Has a Plan For Every Living Creature: Who Will Rise Up, Reach Out, and Follow God's Plan to Fruition?
18/07/202405:00PR Newswire (US)Mercy Medical Center Gastroenterologist Dr. Raymond K. Cross Elected to American College of Gastroenterology's Board of Governors
18/07/202405:00PR Newswire (US)Action-Packed Christian Fiction Takes Readers on a Relatable Journey of Navigating Fears
18/07/202404:38UK RegulatoryJunshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
18/07/202404:20PR Newswire (US)Rokid Partners with vivo to Lead the New Trend of'Spatial Computing + Smartphone'
18/07/202404:10PR Newswire (US)POWERCHINA Promotes Global Sports Development with Construction of Multiple World-class Sports Facilities
18/07/202404:01PR Newswire (US)Aurzen Showcases its BOOM and EAZZE Projector Series at the Latin American Electronics International Trade Show

Your Recent History

LSE
GDR
Genedrive
LSE
EDEN
Eden Research
LSE
MIN
Minoan
LSE
VAST
Vast Resources
LSE
ALBA
Alba Mineral Resources
LSE
PPP
Pennpetro Energy
LSE
JLP
Jubilee Metals
LSE
FLTR
Flutter Entertainment
LSE
CLCO
Cloudcoco
LSE
GKP
Gulf Keystone Petroleum
LSE
THG
Thg
LSE
BGO
Bango
LSE
PANR
Pantheon Resources
LSE
GGP
Greatland Gold
LSE
RRR
Red Rock Resources
LSE
CHLL
Chill Brands
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved